Manish Kohli
YOU?
Author Swipe
View article: Quantum Dot Encoding for In-Solution Single-Molecule Biomarker Counting in Metastatic Prostate Cancer
Quantum Dot Encoding for In-Solution Single-Molecule Biomarker Counting in Metastatic Prostate Cancer Open
Digital assays are in wide development for biomarker quantification at the single-molecule level, but the common use of surface-pulldown steps limits both analytical sensitivity and throughput. Here, we develop surface-free, wash-free, in-…
View article: The future of Ukrainian healthcare: the digital opportunity
The future of Ukrainian healthcare: the digital opportunity Open
Following the dissolution of the Soviet Union in 1991, Ukraine inherited a decaying healthcare system. Significant reform was under way by 2014, laying the framework for creating a robust digital healthcare system. This viewpoint describes…
View article: Efficacy of ProSealTM Laryngeal Mask Airway with or without Introducer-tool Stabilisation for Pressure Controlled Ventilation in Adults Undergoing Elective Surgery: A Randomised Controlled Study
Efficacy of ProSealTM Laryngeal Mask Airway with or without Introducer-tool Stabilisation for Pressure Controlled Ventilation in Adults Undergoing Elective Surgery: A Randomised Controlled Study Open
Introduction: ProSeal TM laryngeal mask airway (PLMA) generates superior oropharyngeal seal pressure (OSP) over other supraglottic airways. However, its efficacy for positive pressure ventilation (PPV) has not been studied as widely. Conce…
View article: Plasma Preparation Strategies for Extracellular Vesicle‐Based Biomarkers in Metastatic Castration‐Resistant Prostate Cancer
Plasma Preparation Strategies for Extracellular Vesicle‐Based Biomarkers in Metastatic Castration‐Resistant Prostate Cancer Open
Extracellular vesicles (EVs) offer a minimally invasive approach for cancer detection and monitoring. However, the lack of standardized methods for clinical biospecimen preparation and EV isolation limits the clinical utility of EV‐based b…
View article: Machine Learning Approaches for Predicting Mortality in Metastatic Castration-Resistant Prostate Cancer
Machine Learning Approaches for Predicting Mortality in Metastatic Castration-Resistant Prostate Cancer Open
Accurate prognostic biomarkers are essential for evaluating survival risks in cancer patients. However, despite the wide use of biomarkers like prostate-specific antigen (PSA) and other clinical factors, achieving high predictive accuracy …
View article: Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer
Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer Open
Plasma proteome profiling can identify novel circulatory DEPs associated with mCRPC state survivals. Overexpression of RRM2 is linked to poor mCRPC survival and its inclusion alongside conventional prognostic factors enhances the predictiv…
View article: Predicting Survival in Metastatic Castration-Resistant Prostate Cancer Patients: Development of a Prognostic Nomogram
Predicting Survival in Metastatic Castration-Resistant Prostate Cancer Patients: Development of a Prognostic Nomogram Open
Patients with metastatic castration-resistant prostate cancer (mCRPC) have a 5-year survival rate of approximately 30%. Accurate prediction of survival in these patients is critical for optimal choice of patient treatment. This study aimed…
View article: Patient Perceptions of Virtual Reality in Cancer Rehabilitation: A Qualitative Study
Patient Perceptions of Virtual Reality in Cancer Rehabilitation: A Qualitative Study Open
This study investigates the use of virtual reality (VR) for cancer rehabilitation (CR) among patients with metastatic prostate cancer (mPC) undergoing androgen deprivation therapy (ADT). Interviews with 20 participants revealed that the en…
View article: Using Machine Learning to Predict Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
Using Machine Learning to Predict Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Open
Non-specific clinical biomarkers have been shown to help identify prognostic risks in cancer patients. However, the accuracy of prognostic biomarkers for predicting survival in patients with metastatic castration-resistant prostate cancer …
View article: Multi-gene risk score for prediction of clinical outcomes in treatment-naïve metastatic castrate-resistant prostate cancer
Multi-gene risk score for prediction of clinical outcomes in treatment-naïve metastatic castrate-resistant prostate cancer Open
Background To determine the performance of a multi-gene copy number variation (MG-CNV) risk score in metastatic tissue and plasma biospecimens from treatment-naïve metastatic castration-resistant prostate cancer (mCRPC) patients for predic…
View article: Adverse prognosis gene expression patterns in metastatic castration‐resistant prostate cancer
Adverse prognosis gene expression patterns in metastatic castration‐resistant prostate cancer Open
Metastatic castration‐resistant prostate cancer (mCRPC) is a heterogeneous disease. Several studies have identified transcriptional subtypes of mCRPC, but comprehensive analysis of prognostic gene expression pathways has been limited. Ther…
View article: Multigene Copy Number Alteration Risk Score Biomarker–Based Enrichment Study Designs in Metastatic Castrate-Resistant Prostate Cancer
Multigene Copy Number Alteration Risk Score Biomarker–Based Enrichment Study Designs in Metastatic Castrate-Resistant Prostate Cancer Open
PURPOSE A composite multigene risk score derived from tumor-biology alterations specific to metastatic castrate-resistant prostate cancer (mCRPC) state was evaluated as a classifier to design biomarker-based enrichment clinical trials. MET…
View article: Qualitative Assessment of Attitudes Towards Telerehabilitation in Patients with Metastatic Prostate Cancer
Qualitative Assessment of Attitudes Towards Telerehabilitation in Patients with Metastatic Prostate Cancer Open
Prostate cancer (PC) is one of the leading causes of cancer-related mortality among men. Androgen Deprivation Therapy (ADT) has been shown to increase survival in men with metastatic PC. Despite its efficacy, ADT’s long-term use adversely …
View article: Figure S4 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Figure S4 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer Open
Figure S4. Biodistribution Study
View article: Figure S2 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Figure S2 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer Open
Figure S2. Capture Efficiency of Trop-2 Expressing Cell Lines.
View article: Data from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Data from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer Open
PURPOSE. Men with metastatic castration-resistant prostate cancer (mCRPC) frequently develop resistance to androgen receptor signaling inhibitor (ARSI) treatment; therefore, new therapies are needed. Trophoblastic cell-surface antigen (Tro…
View article: Figure S2 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Figure S2 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer Open
Figure S2. Capture Efficiency of Trop-2 Expressing Cell Lines.
View article: Figure S1 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Figure S1 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer Open
Figure S1. Correlation of TACSTD2 with Prostate Cancer Cell Surface Markers.
View article: Figure S3 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Figure S3 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer Open
Figure S3. Scatter plot of gene expression for genes shown in Figure 3D isolated from matched anti-EpCAM vs anti-Trop2 captured CTCs at the same timepoint.
View article: Figure S4 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Figure S4 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer Open
Figure S4. Biodistribution Study
View article: Figure S1 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Figure S1 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer Open
Figure S1. Correlation of TACSTD2 with Prostate Cancer Cell Surface Markers.
View article: Figure S3 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Figure S3 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer Open
Figure S3. Scatter plot of gene expression for genes shown in Figure 3D isolated from matched anti-EpCAM vs anti-Trop2 captured CTCs at the same timepoint.
View article: Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancers
Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancers Open
Resistance to the current Androgen Receptor Signaling Inhibitor (ARSI) therapies has led to higher incidences of therapy-induced neuroendocrine-like prostate cancer (t-NEPC). This highly aggressive subtype with predominant small-cell-like …
View article: Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial
Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial Open
Background Muscle mass is important for metastatic prostate cancer survival and quality of life (QoL). The backbone of treatment for men with metastatic castration sensitive prostate cancer (mCSPC) is androgen deprivation therapy (ADT) wit…
View article: A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating “BRCAness” Genotype (ROAR)
A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating “BRCAness” Genotype (ROAR) Open
Background Both germline and somatic BReast CAncer gene (BRCA) mutations are poor prognostic markers in men with localized or metastatic prostate cancer. For instance, men with these mutations often are diagnosed with prostate cancer earli…
View article: Implementation of Precision Oncology into the Diagnostic and Therapeutic Armamentarium: Actionable Takeaways from the 2023 Precision Oncology Summit
Implementation of Precision Oncology into the Diagnostic and Therapeutic Armamentarium: Actionable Takeaways from the 2023 Precision Oncology Summit Open
The 2023 Precision Oncology Summit was held in San Francisco, CA on October 7 th and 8 th , focusing on actionable strategies addressing personalized treatment to improve patient outcomes. This manuscript summarizes the discussion and key …